Skip to content
Back Home
  • Home
  • About Us
    • Our History
    • Our Science
    • Our Partners
  • Scientific Platforms
    • ADCs
    • Publications
  • Team
  • News
  • Contact
Back Home
  • Search
  • Home
  • About Us
    • Our History
    • Our Science
    • Our Partners
  • Scientific Platforms
    • ADCs
    • Publications
  • Team
  • News
  • Contact
Home » Uncategorized » Manhattan BioSolutions secures non-dilutive angel funding
Uncategorized

Manhattan BioSolutions secures non-dilutive angel funding

by Mbio2018|Published May 1, 2018

You may also like

Published August 23, 2021

EVQLV and Manhattan BioSolutions Announce Grant Award from UB CAT

New York City, New York Jun 29, 2021 (Issuewire.com)  – EVQLV, an innovator in developing artificial intelligence to accelerate how biologic therapies reach patients, […]

Published April 8, 2025

Manhattan BioSolutions Secures Expanded Rights to Novel Legumain-Cleavable Topoisomerase 1 Inhibitor (TOP1i) ADC Platform After Successful Multi-Target Validation

Published January 13, 2021

Manhattan BioSolutions to Present at the ACCESS CHINA Forum @JPM WEEK 2021

NEW YORK, NEW YORK, UNITED STATES, January 13, 2021 – Manhattan BioSolutions, Inc. (MABS), an emerging biotechnology company focused on the discovery […]

Published June 25, 2024

Manhattan BioSolutions Partners to Advance Taxoids as Innovative ADC Payloads

Post navigation

  • Back to post list
  • Next post Manhattan BioSolutions has been awarded REACH grant from the New York State Center For Biotechnology at the Stony Brook University

© 2026 Manhattan BioSolutions – All rights reserved

Powered by WP – Designed with the Customizr theme